Literature DB >> 10459309

Mammographic pattern of microcalcifications in the preoperative diagnosis of comedo ductal carcinoma in situ: histopathologic correlation.

G Hermann1, R J Keller, S Drossman, B A Caravella, P Tartter, R A Panetta, I J Bleiweiss.   

Abstract

OBJECTIVE: The comedo subtype of ductal carcinoma in situ (DCIS) is more aggressive than noncomedo DCIS. Differentiating noncomedo DCIS from the more aggressive comedo subtypes on mammography would allow the surgeon to excise comedo DCIS with a wider margin. The mammographic features of microcalcifications associated with nonpalpable comedo DCIS, noncomedo DCIS and benign disease were compared to determine the usefulness of this finding in diagnosis of comedo DCIS.
METHODS: The authors retrospectively and blindly reviewed the mammograms of 91 consecutive patients in whom DCIS was diagnosed by needle localization and surgical excision. An equal number of cases of benign microcalcifications were also reviewed. Microcalcifications were evaluated with respect to pattern, density, configuration and size. These results were correlated with the pathologic findings.
RESULTS: All 16 cases (100%) of linear branching calcifications and 34 (80%) of the 43 cases of linear calcifications were associated with comedo DCIS (p < 0.001). The number of calcifications, the density and the size of clustering were not diagnostic of comedo DCIS. Granular calcifications occurred in noncomedo DCIS and in benign disease associated with noncalcifying DCIS.
CONCLUSION: Comedo DCIS is suggested by the presence of linear and linear branching microcalcifications on mammography.

Entities:  

Mesh:

Year:  1999        PMID: 10459309

Source DB:  PubMed          Journal:  Can Assoc Radiol J        ISSN: 0846-5371            Impact factor:   2.248


  8 in total

Review 1.  What is the malignant nature of human ductal carcinoma in situ?

Authors:  Virginia Espina; Lance A Liotta
Journal:  Nat Rev Cancer       Date:  2010-12-02       Impact factor: 60.716

2.  Attacking breast cancer at the preinvasion stage by targeting autophagy.

Authors:  Virginia Espina; John Wysolmerski; Kirsten Edmiston; Lance A Liotta
Journal:  Womens Health (Lond)       Date:  2013-03

3.  Independent predictors of breast malignancy in screen-detected microcalcifications: biopsy results in 2545 cases.

Authors:  G Farshid; T Sullivan; P Downey; P G Gill; S Pieterse
Journal:  Br J Cancer       Date:  2011-11-03       Impact factor: 7.640

4.  Breast cancer with neoductgenesis: histopathological criteria and its correlation with mammographic and tumour features.

Authors:  Wenjing Zhou; Thomas Sollie; Tibor Tot; Sarah E Pinder; Rose-Marie Amini; Carl Blomqvist; Marie-Louise Fjällskog; Gunilla Christensson; Shahin Abdsaleh; Fredrik Wärnberg
Journal:  Int J Breast Cancer       Date:  2014-10-08

5.  Ductal Breast Carcinoma In Situ: Mammographic Features and Its Relation to Prognosis and Tumour Biology in a Population Based Cohort.

Authors:  Wenjing Zhou; Thomas Sollie; Tibor Tot; Carl Blomqvist; Shahin Abdsaleh; Göran Liljegren; Fredrik Wärnberg
Journal:  Int J Breast Cancer       Date:  2017-02-14

6.  High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision.

Authors:  Oluwole Fadare; Nathan F Clement; Mohiedean Ghofrani
Journal:  Diagn Pathol       Date:  2009-08-19       Impact factor: 2.644

7.  Mammography casting-type calcification and risk of local recurrence in DCIS: analyses from a randomised study.

Authors:  L Holmberg; Y N S Wong; L Tabár; A Ringberg; P Karlsson; L-G Arnesson; K Sandelin; H Anderson; H Garmo; S Emdin
Journal:  Br J Cancer       Date:  2013-01-31       Impact factor: 7.640

8.  Correlation between imaging and pathology in ductal carcinoma in situ of the breast.

Authors:  Marnix A J De Roos; Ruud M Pijnappel; Wendy J Post; Jaap De Vries; Peter C Baas; Lex D Groote
Journal:  World J Surg Oncol       Date:  2004-03-12       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.